Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AngioSoma, Inc. (OTC: SOAN).

Full DD Report for SOAN

You must become a subscriber to view this report.


Recent News from (OTC: SOAN)

AngioSoma Unveils New Logo and Brand Identity
Houston, TX., July 11, 2018 (GLOBE NEWSWIRE) -- AngioSoma (OTC: SOAN) today launched a new corporate logo and website, marking the most dramatic change in its visual identity since 2016. Taking a more modern approach to developing a more differentiated corporate mark, the brighter blue colo...
Source: GlobeNewswire
Date: July, 11 2018 14:32
AngioSoma Prepares for Final FDA Approval Process on Company's Flagship Biologic
HOUSTON, TX, June 25, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is in discussions to engage a respected pharmaceutical regulatory advisory firm to help it navigate the Food and Drug Administration’s (FDA) third and last step in the approval process. If the biologic ...
Source: GlobeNewswire
Date: June, 25 2018 09:30
AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug
HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™, through the FDA approval process.  The regulatory firm will begin with a presubmis...
Source: GlobeNewswire
Date: June, 18 2018 11:44
AngioSoma, Inc. Announces Grant of Patent for Flagship Drug
HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN)  is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship pharmaceutical, Liprostin™ that is intended to treat Peripheral Artery Disease, or PAD. ...
Source: GlobeNewswire
Date: May, 14 2018 12:13
AngioSoma, Inc. (OTC: SOAN) Announces Launch of www.soma-ceuticals.com Website
We are pleased to announce we have initiated our new website, http://www.soma-ceuticals.com to market our Somaceuticals TM line of health supplements. Our innovative supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals. Nutraceuticals lead off...
Source: Business Wire
Date: April, 02 2018 09:30
AngioSoma, Inc. (OTC: SOAN) Announces Completion of Products for Market
We are pleased to announce we are launching a line of supplements under our Somaceuticals TM common identity to be marketed on our upcoming website to be named soma-ceuticals.com. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals. Nutrace...
Source: Business Wire
Date: February, 05 2018 08:00
AngioSoma, Inc. (OTC: SOAN) Reports Esther & Esther Confident in New Revenue Plan
HOUSTON, TX--(Marketwired - Sep 21, 2017) -  AngioSoma, Inc. ( OTC : SOAN ) -- Esther & Esther management has high optimism that its revenue plan could prove successful. The publicly stated plan simply and efficiently drives high volume traffic and interested buyers directly to Est...
Source: Marketwired
Date: September, 21 2017 11:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.0150.01370.0150.0121,989,841
2018-12-170.02360.0150.025750.0115,366,024
2018-12-140.010850.0235650.03950.0114,447,743
2018-12-130.0110.0090.0110.009561,150
2018-12-120.0110.01070.01190.0107125,120

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18884,6671,989,84144.4592Short
2018-12-17658,6005,366,02412.2735Cover
2018-12-146,516,45812,968,99050.2465Short
2018-12-13272,150431,15063.1219Short
2018-12-124,990125,1203.9882Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SOAN.


About AngioSoma, Inc. (OTC: SOAN)

Logo for AngioSoma, Inc. (OTC: SOAN)

lt p gt AngioSoma, Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard of care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease PAD . The Company is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories. lt /p gt

 

 

 

Current Management

  • Alex K. Blankenship / President, CEO
  • Alex K. Blankenship / Chairman
  • David P. Summers, PhD, MBA, F / Chairman Emeritus

Current Share Structure

  • Market Cap: $1,031,265 - 03/16/2018
  • Authorized: 480,000,000 - 05/10/2017
  • Issue and Outstanding: 52,084,067 - 02/14/2018
  • Float: 12,488,734 - 05/10/2017

 


Recent Filings from (OTC: SOAN)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 15 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: February, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: January, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 10 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: December, 29 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 19 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 18 2017

 

 


Daily Technical Chart for (OTC: SOAN)

Daily Technical Chart for (OTC: SOAN)


Stay tuned for daily updates and more on (OTC: SOAN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SOAN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SOAN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SOAN and does not buy, sell, or trade any shares of SOAN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/